

March 8, 2022

DFP AND CHEMIPHAR CONCLUDE LICENSE AGREEMENT FOR DFP-14323

Delta-Fly Pharma, Inc
Nippon Chemiphar Co., Ltd.

We are pleased to announce that Delta-Fly Pharma, Inc. (Head Office: Tokushima, Tokushima; President and CEO, Kiyoshi Eshima; hereinafter, “DFP”) and Nippon Chemiphar Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President and CEO, Kazushiro Yamaguchi; hereinafter, “Chemiphar”) have concluded a license agreement under which DFP grants Chemiphar exclusive rights to market in Japan its patented DFP-14323 that is under development for the treatment of non-small cell lung cancer (NSCLC) Stage III and IV with epidermal growth factor receptor (EGFR) mutation positive.

DFP-14323 binds to aminopeptidase N (a surface marker for cancer stem cells also known as CD13) that appears on the surface of immune-related cells to enhance immune response in cancer patients. It also improves the effectiveness of standard anticancer agents without increasing side effects and, therefore, is expected to be useful for elderly or terminal cancer patients.

DFP-14323 has shown positive results in a clinical phase II study for EGFR mutation positive NSCLC Stage III and IV in combination with currently used anticancer agents. With this agreement, DFP will continue development and will apply for manufacturing and marketing approval for EGFR-mutated NSCLC following consultations with the Pharmaceuticals and Medical Devices Agency (PMDA), and Chemiphar will market this drug in Japan as soon as approval is given.

While anticancer agents with a variety of mechanisms are used to treat NSCLC patients, its mortality is still very high and treatment is sometimes discontinued, especially in elderly and terminal patients. Therefore, more patient-friendly therapies for cancer are needed. The patent covering this drug has been granted in Japan, the U.S., EU, Australia, South Korea, Russia, and Taiwan.

For further information contact:

Public Relations Department, Nippon Chemiphar Co., Ltd.

E-mail: ir@chemiphar.co.jp